New compounds to treat aggressive brain tumors
New anti-glioblastoma metabolic compounds with high potential for Blood Brain Barrier penetration
This study is working on new cancer drugs that can get past the protective barrier in the brain to better treat glioblastomas, with the hope of improving survival and quality of life for patients who haven't had success with current treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Waypath Pharma LLC NIH-funded |
| Lab location | 1 site (Metairie, United States) |
| Project ID | NIH-10543931 on NIH RePORTER |
What this research studies
This research focuses on developing new anti-cancer drugs specifically designed to penetrate the blood-brain barrier, which is a significant challenge in treating glioblastomas. The approach involves modifying existing compounds to enhance their ability to reach and kill glioblastoma cells effectively. By targeting the metabolic pathways of these tumors, the research aims to create therapies that can improve patient outcomes where current treatments have failed. Patients may benefit from these innovative compounds that could potentially lead to better survival rates and quality of life.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma who have limited treatment options.
Not a fit: Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new treatment options for patients with glioblastoma, potentially improving survival and quality of life.
How similar studies have performed: While metabolic approaches to glioblastoma treatment are being explored, this specific method of modifying existing compounds for better blood-brain barrier penetration is relatively novel.
Where this research is happening
Metairie, United States
- Waypath Pharma LLC — Metairie, United States (Active)
Researchers
- Principal investigator: Reiss, Krzysztof — Waypath Pharma LLC
- Study coordinator: Reiss, Krzysztof
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.